C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $10.50.
Separately, BMO Capital Markets reaffirmed an “outperform” rating and issued a $20.00 price objective on shares of C4 Therapeutics in a research note on Tuesday, August 6th.
Read Our Latest Stock Analysis on CCCC
Institutional Inflows and Outflows
C4 Therapeutics Stock Performance
C4 Therapeutics stock opened at $5.53 on Thursday. The company’s 50 day simple moving average is $6.04 and its 200-day simple moving average is $5.81. C4 Therapeutics has a 1 year low of $1.06 and a 1 year high of $11.88. The company has a market capitalization of $383.44 million, a price-to-earnings ratio of -2.91 and a beta of 3.04.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.11. C4 Therapeutics had a negative return on equity of 44.60% and a negative net margin of 367.17%. The company had revenue of $12.01 million for the quarter, compared to analyst estimates of $6.88 million. Equities analysts expect that C4 Therapeutics will post -1.57 earnings per share for the current year.
C4 Therapeutics Company Profile
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Featured Articles
- Five stocks we like better than C4 Therapeutics
- What Investors Need to Know to Beat the Market
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Where to Find Earnings Call Transcripts
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How is Compound Interest Calculated?
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.